Evidence map›Paper›PMID 35955815›Full record

ArticleInternational journal of molecular sciences2022

Structural Evolution of Delta (B.1.617.2) and Omicron (BA.1) Spike Glycoproteins.

Ingrid Guarnetti Prandi, Carla Mavian, Emanuela Giombini, Cesare E M Gruber, Daniele Pietrucci, Stefano Borocci, Nabil Abid, Andrea R Beccari, Carmine Talarico, Giovanni Chillemi

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. The Spike Mutants Website: A Worldwide Used Resource against SARS-CoV-2.International journal of molecular sciences · 2022
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Ingrid Guarnetti PrandiDepartment for Innovation in Biological, Agro-Food and Forest Systems-DIBAF, University of Tuscia, Via S. Camillo de Lellis s.n.c., 01100 Viterbo, Italy.ORCID 0000-0002-3253-1821
Carla MavianEmerging Pathogen Institute, University of Florida, Gainesville, FL 32608, USA.ORCID 0000-0003-3819-5520
Emanuela GiombiniLaboratory of Virology, INMI Lazzaro Spallanzani IRCCS, Via Portuense 292, 00149 Roma, Italy.ORCID 0000-0003-2237-9755
Cesare E M GruberLaboratory of Virology, INMI Lazzaro Spallanzani IRCCS, Via Portuense 292, 00149 Roma, Italy.ORCID 0000-0002-8831-3380
Daniele PietrucciDepartment for Innovation in Biological, Agro-Food and Forest Systems-DIBAF, University of Tuscia, Via S. Camillo de Lellis s.n.c., 01100 Viterbo, Italy.
Stefano BorocciDepartment for Innovation in Biological, Agro-Food and Forest Systems-DIBAF, University of Tuscia, Via S. Camillo de Lellis s.n.c., 01100 Viterbo, Italy.ORCID 0000-0003-4931-3019
Nabil AbidLaboratory of Transmissible Diseases and Biological Active Substances LR99ES27, Faculty of Pharmacy, University of Monastir, Rue Ibn Sina, Monastir 5000, Tunisia.
Andrea R BeccariDompé Farmaceutici SpA, Via Campo di Pile, 67100 L'Aquila, Italy.ORCID 0000-0001-6830-2695
Carmine TalaricoDompé Farmaceutici SpA, Via Campo di Pile, 67100 L'Aquila, Italy.ORCID 0000-0003-4789-0955
Giovanni ChillemiDepartment for Innovation in Biological, Agro-Food and Forest Systems-DIBAF, University of Tuscia, Via S. Camillo de Lellis s.n.c., 01100 Viterbo, Italy.ORCID 0000-0003-3901-6926
Università degli Studi della Tuscia · ITDompé (Italy) · ITIstituto Nazionale per le Malattie Infettive Lazzaro Spallanzani · ITUniversity of Florida · USUniversity of Monastir · TN

Funding

EU H2020-SC1-PHE-CORONAVIRUS-2020Ministero della Salute, 5 per Mille Project 5M-2020-23682104Ministry of Education, Universities and Research Departments of Excellence-2018' Program (Dipartimenti di Eccellenza) to DIBAF-Department of University of Tuscia, Project 'Landscape 4.0-food, wellbeing and environment'.
6 · The paper itself

Abstract

The vast amount of epidemiologic and genomic data that were gathered as a global response to the COVID-19 pandemic that was caused by SARS-CoV-2 offer a unique opportunity to shed light on the structural evolution of coronaviruses and in particular on the spike (S) glycoprotein, which mediates virus entry into the host cell by binding to the human ACE2 receptor. Herein, we carry out an investigation into the dynamic properties of the S glycoprotein, focusing on the much more transmissible Delta and Omicron variants. Notwithstanding the great number of mutations that have accumulated, particularly in the Omicron S glycoprotein, our data clearly showed the conservation of some structural and dynamic elements, such as the global motion of the receptor binding domain (RBD). However, our studies also revealed structural and dynamic alterations that were concentrated in the aa 627-635 region, on a small region of the receptor binding motif (aa 483-485), and the so-called "fusion-peptide proximal region". In particular, these last two S regions are known to be involved in the human receptor ACE2 recognition and membrane fusion. Our structural evidence, therefore, is likely involved in the observed different transmissibility of these S mutants. Finally, we highlighted the role of glycans in the increased RBD flexibility of the monomer in the up conformation of Omicron.

Indexed as

COVID-19Spike Glycoprotein, CoronavirusAngiotensin-Converting Enzyme 2GlycoproteinsHumansMutationPandemicsSARS-CoV-2Angiotensin-Converting Enzyme 2GlycoproteinsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2COVID-19deltamolecular dynamicsomicronSARS-CoV-2spikevariants

Identifiers

PMID35955815
PMCPMC9369368
OpenAlexW4289856861

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.